论文部分内容阅读
目的评价匹多莫德治疗小儿反复下呼吸道感染的临床疗效。方法选取2012年2月~2013年9月本院收治的反复下呼吸道感染的患儿93例,随机分为两组,其中观察组47例,在常规治疗基础上加用匹多莫德,对照组46例,仅采用常规治疗,治疗2周后观察并比较两组患儿临床疗效和免疫功能各指标。结果观察组临床疗效优为28(59.6%)例,良为14(29.8%)例,差为5(10.6%)例,对照组临床疗效优为20(43.5%)例,良为15(32.6%)例,差为11(23.9%)例,两组患儿临床疗效比较差异有统计学意义(P<0.05);观察组CD4+平均增加(10.7±2.1)%,IgE平均减少(131.5±17.2)ng/L,对照组CD4+平均增加(2.3±0.5)%,IgE平均减少(82.3±7.9)ng/L,两组患儿免疫功能各项指标比较差异有统计学意义(P<0.05);观察组与对照组均未有不良反应发生。结论匹多莫德治疗小儿反复下呼吸道感染的临床疗效好,同时改善患儿免疫功能,毒副作用少,值得在临床上予以推广。
Objective To evaluate the clinical efficacy of pidotimod in children with repeated lower respiratory tract infections. Methods Ninety-three children with recurrent lower respiratory tract infection admitted to our hospital from February 2012 to September 2013 were randomly divided into two groups, of which 47 cases in the observation group were treated with Pidotimod on the basis of routine treatment. Group of 46 cases, only conventional treatment, after 2 weeks of treatment were observed and compared the clinical efficacy and immune function of two groups of indicators. Results The clinical efficacy was 28 (59.6%) in excellent observation group, 14 (29.8%) in good condition and 5 (10.6%) in poor observation group. The clinical efficacy was 20 (43.5% %) Cases, the difference was 11 cases (23.9%). There was significant difference in clinical curative effect between the two groups (P <0.05). The average increase of CD4 + in observation group was (10.7 ± 2.1)%, ) ng / L, the average increase of CD4 + in control group was (2.3 ± 0.5)%, and the average IgE was decreased (82.3 ± 7.9) ng / L. There was significant difference in immune function between the two groups (P <0.05). No adverse reactions occurred in the observation group and the control group. Conclusion Pidotimod treatment of children with repeated lower respiratory tract infection has good clinical efficacy, while improving children’s immune function, fewer side effects, it is worth to be clinically promoted.